EU Court Shoots Down TiO2 Hazard Classification, Opening Door For Future Challenges
Executive Summary
Titanium dioxide stakeholders argued successfully in the Court of Justice of the European Union that TiO2’s hazard classification in 2020 under the CLP was based on shoddy science and a flawed interpretation of EU law. The industry win comes as the European Commission is finalizing a regulation to establish new CLP hazard classes, including for endocrine disruptors.
You may also be interested in...
EU Reg Consultant On CLP Revisions: Take A Breath, Cost It Out, Consider ‘Lobbying And Pushing Back’
Louise Witter of UK-based Chemical Legislation Professionals spoke with HBW Insight ahead of the European Commission’s 19 December adoption of a proposal to revise the CLP by introducing new hazard classes, including for endocrine disruptors.
TiO2 Still A California Prop 65 Target; EU Commission Returns To SCCS With New Safety Questions
Titanium dioxide use in cosmetic products is getting another look by the EU’s Scientific Committee on Consumer Safety, with a focus on genotoxicity and exposure via inhalation and oral routes. Stateside, potentially respirable TiO2 continues to be the focus of Prop 65 lawsuits in California.
EU Bans Titanium Dioxide In Supplements, Drugs Given Reprieve, For Now
Titanium dioxide is now officially banned as an ingredient in foods and dietary supplements in the European Union on safety grounds. However, manufacturers can still place products containing the chemical compound on the market for six months, and then any products still on the market can remain until their expiry date. Meanwhile, the European Commission and pharmaceutical companies have three years to find titanium dioxide alternatives for medicines, or justify why it should continue to be used.